UTHR

UTHR

USD

United Therapeutics Corporation Common Stock

$437.330+4.580 (1.058%)

Prix en Temps Réel

Healthcare
Drug Manufacturers - Specialty & Generic
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$432.750

Haut

$440.000

Bas

$430.020

Volume

0.35M

Fondamentaux de l'Entreprise

Capitalisation Boursière

18.8B

Industrie

Drug Manufacturers - Specialty & Generic

Pays

United States

Statistiques de Trading

Volume Moyen

0.79M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $266.98Actuel $437.330Haut $479.5

Actualités Connexes

BusinessWire

United Therapeutics Corporation to Present at Upcoming Investor Conferences

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming

Voir plus
United Therapeutics Corporation to Present at Upcoming Investor Conferences
BusinessWire

United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease

Ongoing EXPAND Study is the First Clinical Trial to Evaluate Xenotransplantation in End-Stage Renal Disease United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its

Voir plus
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $525

HC Wainwright & Co. analyst Andrew S. Fein maintains United Therapeutics with a Buy and raises the price target from $500 to $525.

Voir plus
HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $525
Analyst Upgrades

RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $587

RBC Capital analyst Lisa Walter maintains United Therapeutics with a Outperform and raises the price target from $569 to $587.

Voir plus
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $587
Analyst Upgrades

Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $423

Wells Fargo analyst Benjamin Burnett maintains United Therapeutics with a Equal-Weight and raises the price target from $414 to $423.

Voir plus
Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $423
BusinessWire

United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key

BusinessWire

United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.